Since its inception, Dana Farber has provided state-of-the-art research to cancer patients to improve their cancer and related diseases, diagnosis, treatment and prevention. Dana Farber, a comprehensive cancer center designated by the Harvard Medical School Hospital and the US federal government, is committed to researching and treating new carcinomas.

  With 4,000 medical staff, Brigham and Women's Hospital, BWH has teamed up with Dana Farber, a global cancer treatment and research organization, to form the Dana Farber / Bregan Cancer Center. Clinics for cancer patients are held in Dana Faber, and hospitalizations are held at Brigham and Women's Hospital. The two agencies were linked by flight and merged to form the Dana Farber / Bregan Cancer Center. The Dana Farber / Brigham Cancer Center combines the best cancer research institutions and hospitals in the world to perform comprehensive cancer, surgery, radiation therapy and the latest clinical trials to treat lung, breast and stomach cancer. It is a landmark achievement of researches such as cancer of esophagus, colorectal cancer, liver cancer, pancreatic cancer, leukemia, multiple myeloma, neurogenic tumor, prostate cancer, kidney cancer, uterine cancer, osteosarcoma, head and neck cancer, skin cancer, non-Hodgkin's lymphoma, melanoma tumor Develops the first biomarker CA-125 for ovarian cancer, develops new methods for evaluating and treating prostate cancer, develops advanced brain surgery tumor techniques, and selectively treats internal radiation therapy. There are seven centers for clinical specialization.

1. Digestive Cancer Center

2. Lymphoma Center

3. Breast Cancer Center

4. Gynecologic Oncology Center

5. Melanoma Center

6. Head and Neck Cancer Center

7. Leukemia Center